Cargando…

Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer

There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer. Combining immunotherapy with other targeted therapies may be an effective strategy for advanced prostate cancer. In the present study, we sought to investigate to enhance the efficacy of anti-CTLA-4 thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witt, Kristina, Evans-Axelsson, Susan, Lundqvist, Andreas, Johansson, Martin, Bjartell, Anders, Hellsten, Rebecka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505385/ https://www.ncbi.nlm.nih.gov/pubmed/33786638 http://dx.doi.org/10.1007/s00262-021-02915-6

Ejemplares similares

The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
por: Hellsten, Rebecka, et al.
Publicado: (2019)

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022)

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
por: Canesin, Giacomo, et al.
Publicado: (2017)

Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
por: Hellsten, Rebecka, et al.
Publicado: (2011)

Expression of tSTAT3, pSTAT3(727), and pSTAT3 (705) in the epithelial cells of hormone‐naïve prostate cancer
por: Krzyzanowska, Agnieszka, et al.
Publicado: (2019)

STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
por: Canesin, Giacomo, et al.
Publicado: (2020)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
por: Salvatori, Erika, et al.
Publicado: (2022)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
por: Timmermand, Oskar Vilhelmsson, et al.
Publicado: (2014)

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
por: Huang, Bo-Tsang, et al.
Publicado: (2017)

The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
por: Fridhammar, Adam, et al.
Publicado: (2020)

Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer
por: Bulaon, Christine Joy I., et al.
Publicado: (2023)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model
por: Yoshimoto, Yuya, et al.
Publicado: (2014)

Radiation Dose Escalation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma
por: Takenaka, Wataru, et al.
Publicado: (2020)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
por: Sharma, Naveen, et al.
Publicado: (2019)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
por: Ueki, Hideto, et al.
Publicado: (2023)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
por: Coutzac, Clélia, et al.
Publicado: (2020)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity
por: Li, Yongjiang, et al.
Publicado: (2023)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy
por: Kim, Jihoon, et al.
Publicado: (2022)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide
por: Lee, Woo-Sung, et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T, et al.
Publicado: (2017)

Automatic registration of multi-modal microscopy images for integrative analysis of prostate tissue sections
por: Lippolis, Giuseppe, et al.
Publicado: (2013)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cvfk9oiel50micm726dvbl4epr